Haptena Therapeutics
Haptena Therapeutics develops next-generation immunotherapies for oncogene-driven cancers, integrating precision oncology and immune engineering.
$3.53M Seed ·
Source: startupintros.com
Funding history ↓Signals
Website registeredJul 9, 2025 (16 months old)
About Haptena Therapeutics
Our research focuses on KRAS-mutant tumors to deliver more effective and durable treatment options.
Funding rounds
- Seed · $3.53MSource: startupintros.com
- Website created
Founders and team
CA
Chiara Ambrogio Co-Foundersource: haptena.comRC
Roberto Chiarle Co-Foundersource: haptena.com
Companies like Haptena Therapeutics
BBreakthru Medicine$60M Series A · Feb 2026
EEngimmune Therapeutics$16M Seed · May 2022OOna Therapeutics$86.6M Series B+ · Oct 2026
DDelphia Therapeutics$67M Series A · May 2024
FFoRx Therapeutics$50M Series A · Dec 2025
LLever Bio$10.09M Seed · Dec 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/haptena-therapeutics (get a free API key).